XML 35 R23.htm IDEA: XBRL DOCUMENT
v3.21.1

Collaborations and Other Arrangements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Schedule of significant milestones and revenue recognized | The table below summarizes the net amount of significant milestones (deferred) capitalized at March 31, 2021 and December 31, 2020 for the compounds included in this collaboration:
| Net Milestones (Deferred) Capitalized (1) as of:
Product Family | March 31, 2021 | December 31, 2020
Jardiance (2) | $ | 151.2 |  | $ | 156.2 |
Trajenta (3) | 108.1 |  | 114.6 |
Basaglar | (163.3) |  | (168.0) |
(1) In connection with the regulatory approvals of Basaglar in the U.S., Europe, and Japan, milestone payments received were recorded as contract liabilities and are being amortized through the term of the collaboration (2029) to collaboration and other revenue. In connection with the regulatory approvals of Jardiance and Trajenta, milestone payments made were capitalized as intangible assets and are being amortized to cost of sales through the term of the collaboration. This represents the amounts that have been (deferred) or capitalized from the start of this collaboration through the end of the reporting period, net of amount amortized. (2) The collaboration agreement with Boehringer Ingelheim for Jardiance ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto. (3) The collaboration agreement with Boehringer Ingelheim for Trajenta ends upon expiration of the compound patent and any supplementary protection certificates or extensions thereto. The following table summarizes our net product revenue recognized with respect to Basaglar and collaboration and other revenue recognized with respect to the Jardiance and Trajenta families of products:
| Three Months Ended March 31, |  |
Product Family | 2021 |  | 2020 |  |  |  |
Jardiance | $ | 312.0 |  |  | $ | 267.5 |  |  |  |  |
Basaglar | 246.6 |  |  | 303.7 |  |  |  |  |
Trajenta | 94.6 |  |  | 93.2 |  |  |  |  |
The following table summarizes our net product revenue recognized with respect to Olumiant:
| Three Months Ended March 31, |  |
| 2021 |  | 2020 |  |  |  |
Olumiant | $ | 193.8 |  |  | $ | 139.7 |  |  |  |  |

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration